Kornimate/medical-research-clean huggingface dataset:
examining the distal gut microbiome after spinal cord injury

Conditions: Spinal Cord Injury

Summary: the purpose of this research study is to learn more about the causes of gastrointestinal dysfunction after spinal cord injury. it has been thought that the microbiome (the community of bacteria in the body) may be one such cause. the study will examine whether changes in the distal gut microbiome are related to gastrointestinal dysfunction in persons with spinal cord injury and non-disabled controls.


Eligibility criteria:
persons with a spinal cord injury: inclusion criteria: 1. age 18-65 2. ≥ 1 year post-injury 3. spinal cord injury resulting in tetraplegia or paraplegia (c5-t6) and motor complete or incomplete (ais a-c) impairment. injury level and impairment will be confirmed by an american spinal injury association (asia) exam conducted less than 2 years before study entry. if longer than 2 years, a certified rater will repeat the exam. 4. self -reported history of constipation or other gastrointestinal dysfunction (e.g., extended bowel care time or difficulty in bowel emptying) 5. willingness to participate in the study exclusion criteria: 1. currently hospitalized 2. american spinal injury association (ais) d-e 3. self-reported history of crohn's disease or diverticulitis, gastric blockage/obstruction or swallowing disorder 4. gastrointestinal surgery ≤ 3 months prior to study 5. implanted cardiac pacemaker, spinal cord stimulator, morphine (pain), or intrathecal pump 6. concurrent use of surface functional electrical stimulation (fes) neurologically-intact persons: inclusion criteria: 1. age 18 or over 2. willingness to participate in the study exclusion criteria: 1. self-reported history of crohn's disease or diverticulitis, gastric blockage/obstruction or swallowing disorder 2. gastrointestinal surgery ≤ 3 months prior to study 3. implanted cardiac pacemaker, spinal cord stimulator, morphine (pain), or intrathecal pump
an open trial of cysteamine treatment in schizophrenia

Conditions: Schizophrenia; Schizoaffective

Summary: the purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.

despite the availability of numerous antipsychotics, the treatment of schizophrenia is very unsatisfactory. many patients have persistent positive psychotic symptoms or negative symptoms despite treatment, and any improvement in cognitive function is small. new approaches to the pharmacotherapy of schizophrenia that are not based primarily on dopaminergic blockade are needed. the rationale for a trial of cysteamine comes from the evidence that cysteamine increases brain concentrations of brain-derived neurotrophic factor. we will conduct an open-label study of tolerability and efficacy of cysteamine as an adjunct to second-generation antipsychotics in schizophrenia and schizoaffective subjects with partially responsive symptoms. our objectives are to determine the safety and tolerability of cysteamine administered as an adjunct to second-generation antipsychotic drugs in adult outpatients with partially-responsive schizophrenia. additionally, we are evaluating the effect of cysteamine on the positive and negative symptoms of schizophrenia as measured by changes in the positive and negative symptom scale (panss), and on cognitive impairment as measured by the brief assessment of cognition in schizophrenia (bacs).

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * 18-60 years of age * residual symptoms, as defined by both 1 \& 2: 1. at least one panss positive symptom item score \> 4, or at least two items with a score \> 3 2. at least one panss negative symptom item score \> 4, or at two items with a score \> 3 * no clinically significant change in symptoms for at least one month * on the same psychotropic medication(s) \> 2 weeks * taking a second-generation antipsychotic (olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, or clozapine) * provision of written informed consent exclusion criteria: * meets criteria for current major depressive disorder * abnormal hepatic function (ast or alt \> 2.5 x the upper limit of normal, or bilirubin \> 1.5 x the upper limit of normal) * abnormal renal function (bun or creatinine \> 1.5 x the upper limit of normal) * presence of any unstable or untreated medical disorder * any history of seizure disorder, hiv, or diagnosis of aids * any abnormal lab test result that is judged to be clinically significant by the investigators * pregnancy, breast feeding, or female and of child-bearing potential who is not using any contraceptive method * present danger to self or others
litt combined with early use of temozolomide for recurrent glioblastomas

Conditions: Recurrent Glioblastoma

Summary: this study aims to investigate the safety and efficacy of laser interstitial thermal therapy (litt) combined with postoperative early use of temozolomide in treating recurrent glioblastomas.

this is an open-label, non-randomized phase ii study, planning to recruit about ten patients. the primary objective of this study is to investigate the safety of mri-guided litt in combination with the early application of temozolomide. the secondary outcome is to explore the efficacy of mri-guided litt combined with the early use of temozolomide in treating recurrent glioblastomas.

Eligibility criteria:
inclusion criteria: 1. imaging (pet-mri) indicates tumor progression or recurrence 2. patient ≥18 years old 3. the tumor was the first-time recurrence 4. the pathology of the tumor is glioblastoma (idh wild-type, who grade 4) 5. mri indicated a single tumor or multiple tumors with visual enhancement =\<3cm 6. maximum tumor diameter: single tumor =\<3cm; multiple tumors, targeted lesion =\<3cm 7. single tumor or one of the multiple tumor lesions involved deep functional areas such as the insula lobe or thalamus 8. kps score \>=60 within 30 days before treatment 9. no serious liver or kidney dysfunction 10. patients must be able to understand how to sign the informed consent document exclusion criteria: 1. the tumor crossed the midline or involved bilateral cerebral hemispheres 2. inability to perform mri examination or intolerance to mri contrast agent 3. there is an active infection of the patient 4. the patient had abnormal coagulation function 5. imaging before treatment indicated signs of cerebral hernia or midline displacement \> 1.0cm 6. the patient received radiotherapy, chemotherapy (including immunotherapy), or other therapeutic measures after tumor recurrence 7. patients who have participated in clinical trials of any other drug or medical device within three months of the screening. 8. kps score =\<50 points

Keywords: gbm glioblastoma litt laser interstitial thermal therapy
ctdna methylation sequencing for myeloma

Conditions: Multiple Myeloma

Summary: 1. to carry out research on minimal residual disease (mrd) monitoring in patients with multiple myeloma (mm) based on plasma circulating tumor dna (ctdna) methylation sequencing, which aims to explore new mrd detection methods for mm; 2. carry out ctdna-based methylation sequencing in newly diagnosed, remission, and, relapsed mm patients, to track the clonal evolution patterns; and explore the in the initial diagnosis-remission-relapse stage of mm, track the clonal evolution characteristics of methylation profiles in mm patients during the disease progression.


Eligibility criteria:
inclusion criteria: - for myeloma patients: i) age no less than 18 and no more than 75; ii) diagnosed with symptomatic multiple myeloma according to imwg consensus; iii) provide informed consent in accordance with the declaration of helsinki. - for healthy controls: i) age no less than 18 and no more than 75; ii) provide informed consent in accordance with the declaration of helsinki. exclusion criteria: - for myeloma patients: i) insufficient amount of peripheral blood obtained; ii) methylation sequencing failed due to technical reasons. - for healthy controls: i) insufficient amount of peripheral blood obtained; ii) methylation sequencing failed due to technical reasons.

Keywords: circulationg tumor dna methylation sequencing minimal residual disease clonal evolution
a study of fluconazole in the prevention of fungal infections in hiv-infected patients living in areas where fungal infections are common

Conditions: Mycoses; HIV Infections; Coccidioidomycosis

Summary: to compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among hiv-infected patients with cd4 lymphocyte counts \< 250 cells/mm3 who are living in the coccidioidal endemic area.

patients are randomized to receive either fluconazole or placebo daily.

Eligibility criteria:
inclusion criteria patients must have: * documented hiv infection. * cd4 count \< 250 cells/mm3. * no active coccidioidomycosis or other fungal disease requiring systemic antifungal therapy. * residence in area considered to be endemic for coccidioides immitis. * consent of parent or guardian if under legal age of consent. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * unable to take oral medication. * positive serum cryptococcal antigen. concurrent medication: excluded: * systemic antifungal therapy. patients with the following prior conditions are excluded: history of hypersensitivity to azole or imidazole compounds. prior medication: excluded: * systemic antifungal agents within 2 weeks prior to study entry.

Keywords: mycoses fluconazole acquired immunodeficiency syndrome aids-related complex coccidioidomycosis
multi-strain probiotic in the management of ibs-d

Conditions: Irritable Bowel Syndrome

Summary: 1. to assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in ibs patients. 2. to assess the efficacy of a multi-strain probiotic supplement as a treatment option for ibs in a tertiary referral centre

background: accumulating evidence supports the view that an imbalance of gut bacteria contributes to ibs, and that increasing the mass of beneficial species may reduce the numbers of pathogenic bacteria and help alleviate symptoms. methods: in this double-blind trial 360 adult patients with moderate-to-severe symptomatic diarrhea-predominant ibs (ibs-d) were randomized to treatment with the multi-strain probiotic (bio-kult®; 14 different bacterial strains; 8 billion colony-forming units per day) or placebo for 16 weeks. the change in severity and frequency of abdominal pain was the primary outcome measure.

Eligibility criteria:
inclusion criteria: 1. diagnosed case of ibs using rome iii criteria 2. absence of red flag sign: anemia, fever, wt loss, per rectal bleeding, nocturnal frequency, family history of inflammatory bowel disease (ibd), cancer 3. age 18-55 years 4. no probiotics used in prior 3 months. 5. agreed not to start any other drug unless clinically indicated. 6. no antibiotics in previous 2 months of enrolment. exclusion criteria: 1. age\ 55 years 2. previous treatment with probiotics within last 3 months 3. pregnant or lactating females 4. concurrent severe illness (uncontrolled diabetes mellitus, renal dysfunction, liver disease, hyper and hypothyroidism) 5. chronic organic bowel disorders e.g. inflammatory bowel diseases, tuberculosis, diverticular disease etc 6. any previous gastrointestinal surgery
pharmacokinetics of dexamethasone in childhood all and reduction in bone mineral density

Conditions: Acute Lymphoblastic Leukemia

Summary: the goal of this observational study is to learn about, the systemic exposure to dexamethason in childhood acute lymphatic leukemia (all). the main questions it aims to answer are: * how does the intake of dexamethasone correlate with systemic exposure to dexamethason? * does systemic exposure to dexamethasone correlate with a reduction in bone mineral density? participants will: * continue to receive the best available therapy for all in western europe. * have blood samples taken from their central line to measure dexamethasone levels. * when standard lumbar punctures are done as part of treatment, a sample of cerebrospinal fluid will also be taken to analyze dexamethasone. * visit the clinic four times for a dxa scans to measure bone density and vertebral fracture assessment: within three weeks of starting treatment, six months after starting treatment, one month after finishing treatment, and one year after finishing treatment. biomarkers related to bone health will also be collected on these days. additionally, participants will fill out questionnaires to track their daily physical activity levels.


Eligibility criteria:
inclusion criteria: * a diagnosis of acute lymphoblastic leukaemia * age 1-17.9 years exclusion criteria: * down syndrome
establishment of big data platform and biobank for colorectal tubular adenoma lesions

Conditions: Colorectal Tubular Adenoma

Summary: colorectal tubular adenoma is the most common precancerous lesion of colorectal cancer, and the point is that its precise prevention and treatment can reduce the incidence of colorectal cancer.however, the epidemiological characteristics of colorectal tubular adenoma in china are unclear, the rate of missed diagnosis by colonoscopy is high, and the existing diagnosis and treatment techniques are lack of unified quality control standards,which makes it difficult to diagnose and achieve accurate prevention and control. how to improve the precise prevention and treatment of colorectal tubular adenoma and reduce the incidence of colorectal cancer is a major clinical scientific problem that needs to be solved urgently. for this purpose, this study was conducted in colorectal guided by the needs of accurate prevention and treatment of tubular adenoma lesions,and a multi-center colorectal tubular adenoma data management platform and a high-risk population database covering a full range of data including demographic characteristics, lifestyle factors, clinical information, endoscopic data and pathological images were established, biological sample databases of patients with pathological changes and high-risk populations were established, and data quality control and sample quality control standards were formulated standards-based. the pathological prediction model and accurate risk assessment system of colorectal tubular adenoma were constructed by the pathological database.


Eligibility criteria:
inclusion criteria: voluntarily sign informed consent; colorectal tubular adenoma was diagnosed according to jsge clinical guidelines they are between 18 and 70 years old exclusion criteria: refuse to sign the informed consent patients who were judged by the investigator to be unsuitable for participation in this study. the diagnosis is not tubular adenoma of colorectal or other adenomas according to jsge clinical guidelines age \ 70
study of myasthenic crisis in china

Conditions: Myasthenia Gravis; Myasthenic Crisis

Summary: this study is a multicenter, prospective, observational research. it will register the basic demographic information, medical history characteristics, clinical features, auxiliary examinations, treatment, outcomes of tracheal intubation/ventilator related events, and clinical outcomes of myasthenic crisis patients. the objectives including: 1. obtain epidemiological data of mc in china; 2. establish a standardized registration system for mc patients in china; 3. explore the epidemiology, clinical characteristics, serological characteristics, clinical characteristics of mc, predisposing and predictive factors, extubation process/time, weaning/extubation outcome and predictors of clinical outcome in chinese mc patients.


Eligibility criteria:
inclusion criteria: * clinical history and signs of fluctuating weakness and fatigability; * seropositivity forachr/muskantibodies; * if negative or the tested antibodies, positive repetitive nerve stimulation(rns) at low frequency(2-5hz) is required; * crisis: a serious, life-threatening, rapid worsening of mg requiring intubation or noninvasive ventilation to avoid intubation. * impending crisis: rapid clinical worsening of mg that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks) with blood gases suggest hypoxia (oxygen saturation \ 50mmhg). exclusion criteria: * the rns had over 100% increase after high frequency stimulation or r2 repeats,to differentiate from lambert-eaton syndrome and congenital mg. * except when intubation or noninvasive ventilation are employed during routine postoperative management.
a phase ii study of sintilimab combined with anlotinib in treatment of ed-sclc

Conditions: Small Cell Lung Cancer Extensive Stage

Summary: this is a the researchers launched, single-center, prospective, open-label, single arm ,phase ii clinical study of sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the efficacy and safety. 23 patients are expected to be enrolled in this study.

subjects will receive sintilimab 200mg, iv, q3w and anlotinib 12mg, po, qd，d1-14, q3w treatment until disease progression, unacceptable toxicity, or death.

Eligibility criteria:
inclusion criteria: * aged ≥ 18, regardless of gender . * histologically or cytologically confirmed small cell lung cancer . * the time after the end of first-line treatment was less than 6 months . * subjects must have measurable diseases as defined in recist v1.1 . * eastern cooperative oncology group (ecog) performance status scores are 0-2 . * adequate hematologic and end organ function . * capable of understanding the trial nature and voluntarily signing the written informed consent form . exclusion criteria: * radiographic findings showed that the tumor involved large blood vessels or was poorly demarcated from them . * radiographic findings showed significant pulmonary cavitation or necrotizing tumor . * active brain metastasis or meningeal metastasis . * with other malignant tumors in the past 5 years, except cancers that have been cured significantly or can be focally cured, e.g. basosquamous carcinoma of skin, or carcinoma cervix in situ . * with interstitial lung disease, including drug- induced interstitial lung disease or radiation pneumonitis . * with clinically significant cardiovascular disorder . * prior exposure to any immune checkpoint inhibitors, including but not limited to other anti-ctla-4, anti-pd-1 or anti-pd-l1 antibodies . * prior exposure to anti-vegfr therapy . * known hypersensitivity to study drug or any of its excipients . * treatment with any other investigational agent or participation in another clinical trial within 4 weeks prior to first administration . * other conditions that the investigator thinks unsuitable in this study .
abdominal massage in enteral nutrition patients

Conditions: Enteral Nutrition; Gastrointestinal System--Abnormalities

Summary: complications related to the gastrointestinal system may arise in patients receiving enteral nutrition through continuous and bolus infusion. these complications include constipation, diarrhea, nausea, vomiting, abdominal distension, increased gastric residual volume, and abdominal pain. the aim of this study is to determine the impact of abdominal massage applied to patients receiving enteral nutrition through continuous or bolus infusion on gastrointestinal system functions. for this purpose, 164 patients meeting the inclusion criteria will be randomized, and four groups will be defined. half will constitute the experimental group, and the others will form the control group. in our study, the effects of massage on symptom control will be evaluated by comparing symptoms in patients receiving both forms of nutrition. thus, the evaluation and control of medical conditions (symptoms) such as constipation, diarrhea, vomiting, increased abdominal distension, and increased gastric residual volume are targeted.


Eligibility criteria:
inclusion criteria: * patients in intensive care * those aged 18 and above * patients being fed through a nasogastric tube * patients on the first day of enteral nutrition * patients without wounds in the abdominal region * those who have not undergone abdominal surgery in the last 6 months * patients not receiving radiotherapy/chemotherapy * patients without a diagnosis of bowel obstruction * patients without diarrhea and constipation * patients with a glasgow coma scale (gks) \> 3 * those with an apache ii score \> 16 * patients not taking prokinetic agents * patients not taking laxative medications * patients without any contraindications for abdominal massage (to be determined in consultation with the primary physician) exclusion criteria: * patients for whom enteral nutrition is discontinued during the study * patients with interrupted enteral nutrition * patients who have started prokinetic agents * the study will be terminated for patients who have started laxative medication.

Keywords: enteral nutrition continuous and bolus infusion abdominal massage gastrointestinal system function
efficacy of ear acupuncture in preventing chemotherapy induced nausea and vomiting in cancer patients

Conditions: Pediatric Cancer; Chemotherapy-induced Nausea and Vomiting; Chemotherapy Effect

Summary: chemotherapy is a cancer therapy performed on advanced cancer with quite good success, but this therapy has quite a lot of side effects. chemotherapy induced nausea and vomiting or commonly known as cinv, is a condition of nausea and vomiting experienced by cancer patients undergoing chemotherapy, with a prevalence of around 80% of all patients undergoing chemotherapy, and 40% has the potential to become severe. this study aims to determine the efficacy of a new acupuncture modality, namely the press needle, in preventing cinv symptoms in pediatric patients with cancer undergoing chemotherapy.

the study was conducted using a randomized controlled clinical trial (rct) design in 64 pediatric cancer patients undergoing chemotherapy who were randomized into 2 groups, namely: (1) standard medical therapy as the control group; and (2) a combination of standard therapy with press needle acupuncture as the treatment group. the ear acupuncture points used are shenmen and stomach, and one body acupuncture point is pc6. outcome measurements were carried out in the form of the rinvr questionnaire to assess the intensity of nausea and vomiting measured at 4 times: (1) 12 hours before chemotherapy; (2) 12 hours after chemotherapy; (3) 3 days after chemotherapy; (4) 7 days after chemotherapy.

Eligibility criteria:
inclusion criteria: * pediatric patients with cancer who are undergoing chemotherapy. * age 6 - 18 years. * patients with platelet counts \> 20,000/μl and neutrophil values \> 1,000/μl. * willing to follow the research. exclusion criteria: * patients with local infection in the puncture area. * patients with anatomic abnormalities in the auricle. * did not complete the acupuncture therapy until it was finished (three days after chemotherapy).

Keywords: acupuncture ear acupuncture cinv cancer press needle